Cross-Border Cancer Care

Advanced Cancer Treatment in China

When Standard Options Are No Longer Enough

For selected cancers and complex cases, China may offer treatment capabilities and emerging therapies not yet widely available in North America.

Explore Your Treatment Options

Emerging Therapies

China-first innovation in cancer medicine

China-first innovative cancer medicines, including next-generation ADCs, bispecific antibodies and biomarker-directed therapies

CAR-T and advanced cellular therapies for selected blood cancers and solid tumors

High-complexity cancer surgery for anatomically difficult, recurrent or previously considered unresectable tumors

Specialized oncology teams for gastric, lung, blood, liver, esophageal and nasopharyngeal cancers

Clinical trials for advanced and treatment-resistant cancers within a rapidly expanding oncology research ecosystem

Why China

Why China Is Becoming a Global Oncology Innovation Hub

Advances in cellular therapy, antibody-drug conjugates, bispecific antibodies and biomarker-driven medicine are creating new options beyond established cancer treatment pathways.

China has become one of the world’s fastest-growing oncology innovation ecosystems, bringing together academic medical centers, cancer clinical trials, molecular testing and China-originated medicines. In selected cancers, innovative therapies may become available earlier, through different indications or within clinical programs not yet broadly accessible in North America.

CAR-T Therapy for Solid Tumors

A new frontier beyond blood cancer

Chinese research teams are advancing some of the world’s most closely watched solid-tumor CAR-T programs, particularly therapies targeting CLDN18.2-positive gastric and other gastrointestinal cancers.

Why it matters: CAR-T is beginning to move beyond blood cancers into selected solid tumors, creating new possibilities for patients with limited treatment options.

Next-Generation ADCs and Bispecific Antibodies

Precision treatment designed to reach difficult targets

China is playing an increasingly important role in the development of antibody-drug conjugates and bispecific or multispecific antibodies across gastric, lung, liver, breast, gynecologic and hematologic cancers.

Why it matters: ADCs and bispecific antibodies may create new biomarker-driven options after standard targeted therapy, chemotherapy or immunotherapy stops working.

China-First Innovative Medicines and Clinical Trials

Earlier access to emerging therapies

A growing number of oncology medicines are first developed, first studied or first approved in China, including novel-mechanism drugs, cellular therapies and T-cell engagers.

Why it matters: A treatment may be available in China before it is broadly accessible in North America, either through approval, expanded institutional access or a cancer clinical trial.

Cancer Areas

Specialized expertise across key cancer types

Gastric and Gastroesophageal Cancers

One of China’s most active areas of therapeutic innovation

Potential options include CLDN18.2-directed CAR-T, biomarker-driven ADCs, bispecific antibodies, new targeted medicines, clinical trials and complex upper gastrointestinal surgery.

Who may consider this: Patients seeking additional options after recurrence, metastatic progression or standard treatment, particularly when molecular testing identifies an actionable biomarker.

Molecularly Defined Lung Cancer

New options after targeted therapy resistance

China’s lung cancer research ecosystem is advancing next-generation targeted therapies, ADCs, bispecific antibodies and trials for EGFR-, HER2-, MET-, RET- and ROS1-altered disease.

Who may consider this: Patients whose molecularly defined lung cancer has progressed after established targeted therapy or who are exploring a biomarker-matched clinical trial.

Relapsed or Refractory Blood Cancers

A rapidly expanding cellular therapy ecosystem

Potential options include CD19- or BCMA-directed CAR-T, dual-target CAR-T, bispecific antibodies, T-cell engagers and novel cellular therapy trials.

Who may consider this: Patients with relapsed or refractory lymphoma, leukemia or multiple myeloma who are evaluating CAR-T, bispecific antibodies or treatment after prior cellular therapy.

Liver Cancer

Innovation across systemic, interventional and surgical treatment

Leading programs combine immunotherapy, targeted medicines, clinical trials, interventional oncology, ablation, radiotherapy, conversion therapy and complex hepatobiliary surgery.

Who may consider this: Patients with advanced, recurrent, vascular-involving or previously unresectable liver cancer who need an integrated multidisciplinary review.

Esophageal Cancer

Emerging therapies supported by multimodality care

Potential options include immunotherapy-based combinations, ADCs, perioperative trials, chemoradiation, robotic surgery and complex salvage treatment.

Who may consider this: Patients with locally advanced, recurrent or treatment-resistant esophageal cancer who are evaluating clinical trials, multimodality treatment or complex surgery.

Nasopharyngeal and Selected Head and Neck Cancers

Specialized expertise in cancers more common in East Asia

Selected centers combine active clinical research with precision radiation, re-irradiation, salvage surgery, EBV-related monitoring and multidisciplinary care.

Who may consider this: Patients with recurrent or previously irradiated nasopharyngeal and selected head and neck cancers who need highly specialized multidisciplinary care.

Who This Is For

Designed for Patients Seeking More Options

Beyond Standard Options

For patients considering treatment beyond their current pathway.

Innovative Medicines or Trials

For patients looking for emerging drugs, cellular therapies or clinical trials.

Complex Surgery

For patients seeking a second opinion on advanced or difficult procedures.

Recurrence or Resistance

For patients exploring additional options after recurrence or treatment failure.

Confidential Intake

Request a Confidential Case Review

If you are exploring additional treatment options, share the information below. Our team will conduct an initial review to determine whether China may offer a meaningful clinical opportunity for your case.

01Tell us more about your treatment needs

Tell us about your current treatment status so our team can better understand where you are in your care journey.

Are you currently undergoing any active treatment?

02What are your primary goals in exploring medical care in China?

Please rank the following factors based on their importance (Rank 1 = Highest Priority). You only need to rank at least one goal — unranked goals will not block submission. Use each rank from 1 to 5 once — no two goals may share the same rank, and ranks must be assigned in order (1, then 2, then 3 …).

Access to Innovative Options

Options distinct from your current plan.

Rank

Cost Efficiency

Comparable care and treatment protocols at a lower out-of-pocket cost.

Rank

Specialist Expertise

Comparable treatment options delivered by specialists with extensive experience and expert clinical judgment.

Rank

Streamlined Access & Timeliness

Similar care pathways with shorter wait times.

Rank

Other Considerations

e.g., second-opinion validation, family support, specific geographical preferences, or TCM integration.

Rank

Please specify your other considerations

03How would you prefer we contact you?

Your information is kept confidential and is only used to prepare your case review and coordinate your care. See our Privacy Policy for details.

Phone Call

Optional

Text Alert Subscription

Get timely text alerts about your case coordination — appointment reminders, travel and visa updates, and important status changes.

Mobile number for text alerts

I consent to receive SMS text messages from LotusBridge Health at the mobile number above. Message frequency varies (typically 2–5 messages per month, more around scheduled appointments). Standard message and data rates may apply from your carrier. Reply HELP for assistance or STOP to cancel at any time. By checking this box you agree to our Terms of Service and Privacy Policy.

No phone number or consent is required unless you choose text alerts. You will not be subscribed to text alerts unless you check the box above. You can opt out at any time by replying STOP to any message.

Please do not use this form for medical emergencies.

All submissions are treated as strictly confidential.

Every patient deserves to know whether a better treatment opportunity exists.

LotusBridge provides medical navigation and coordination services. Final medical decisions are made by licensed treating physicians and participating institutions.

Explore Your Treatment Options